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Abstract
Objective: Quantitative assessment of active bone marrow (BM) in vivo is yet to be well-defined. This study aims to compare
total body BM volume estimations obtained from use of both18F-FLT PET/CT and 18F-FDG PET/CT in order to consolidate
higher cellular proliferation rates with imaging the highly active red BM in pancreatic cancer.
Methods: This phase I pilot study includes seven patients with pancreatic cancers who underwent both 18F-FLT and 18F-FDG
imaging each acquired within a week’s duration. A CT-based classifier is used for segmenting bone into cortical and trabecular
regions. The total BM volume is determined through statistical thresholding on PET activity found within the trabecular bone.
Results: Results showed that 18F-FLT measures of red BM volume (RBV) were higher than those obtained from 18F-FDG
(∆=89.21 ml). RBV obtained using 18F-FLT in males were found to have high correlation with measured weight (R2=0.61) and
BMI (R2=0.70). The red BM fraction obtained from 18F-FLT was significantly different between males and females, with
females showing much higher red bone matter within the trabecular bone (p<0.05). In contrast to 18F-FLT, 18F-FDG BM
measurements showed that RBV was significantly different between males and females (p<0.05). Results also show that
spinal activity SUV threshold for red BM segmentation is significantly different between 18F-FLT PET and 18F-FDG PET (p<0.05).
Conclusion: By combining 18F-FLT-PET and 18F-FDG-PET, this study provides useful insights for in vivo BM estimation through
its proliferative and glycolytic activities.
Key words: PET/CT, 18F-FLT, 18F-FDG, bone marrow imaging, image processing
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Özet
Amaç: In vivo aktif Kemik İliği’nin (Kİ) kantitatif değerlendirmesi tam olarak tanımlanmış değildir. Bu çalışmadaki amaç
18F-FLT ve 18F FDG görüntüleme yöntemleriyle kemik iliğinin hücresel bölünme aktivitesi ile glikolitik aktivite ile tanımlanan
hacimlerinin mukayesesini yapmaktır. Bu spesifik çalışmaya esas olan ana çalışma, pancreas kanserli hastalarda başlatılmış bir
faz 1 araştırmasıdır.
Yöntem: By faz 1 çalışmaya pancreas kanseri olan yedi hasta dahil edilmiştir, bir hafta içerisinde hem 18F-FLT hem 18F-FDG
görüntülemesi yapılmış, kemik dokusunu kortikal ve trabeküler bölgelere ayırmak için BT bazlı bir sınıflama kullanılmıştır. Total
Kİ hacmi, trabeküler kemikteki PET aktivitesinin istatiki bir eşikleme metodu uygulanarak belirlenmiştir.
Bulgular: 18F-FLT ile elde edilen kırmızı Kİ hacmi (KKİ) 18F-FDG ile saptanadan daha yüksek bulunmuştur (∆=89,21 ml). 18F-FLT
ile saptanan KKİ erkeklerde ağırlık (R2=0,61) ve KKİ (R2=0,70) ile yüksek korelasyon göstermektedir. 18F-FLT ile elde edilen
kırmızı Kİ fraksiyonu erkekler ve kadınlar arasında anlamlı farklılık göstermekteydi, kadınlarda trabeküler kemik içerisinde daha
yüksek kırmızı kemik maddesi bulunmaktaydı (p<0,05). 18F-FLT’nin aksine 18F-FDG Kİ ölçümleri KKİ’nin kadınlar ve erkekler
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arsında anlamlı farklılık gösterdiği saptandı (p<0,05). Sonuçlar kırmızı Kİ segmentasyonu için spinal aktivite SUV eşiğinin 18F-FLT
PET ile 18F-FDG PET arasında anlamlı derecede farklı olduğunu gösterdi (p<0,05).
Sonuç: Bu çalışma 18F-FLT-PET ile 18F-FDG-PET’in birleştirilmesinin proliferative ve glikolitik aktivitelerine bağlı olarak in vivo Kİ
tahminine önemli katkı sağladığını göstermektedir.
Anahtar kelimeler: PET/CT, 18F-FLT, 18F-FDG, kemik iliği görüntülemesi, görüntüleme işlemi
Çıkar Çatışması: Yazarlar bu makale ile ilgili olarak herhangi bir çıkar çatışması bildirmemiştir.

Introduction

PET/CT. The study that was based on a large population
is the first of its kind in estimating intraosseous volume
(IBV) by using SUV measures obtained from glucose
uptake (17). Since glucose consumption in the IBV is
indirectly correlated to the glycolytic activity of the BM, the
distribution of the FDG PET/CT activity serves as a potent
marker for estimating the red marrow within the skeleton.
Prior to 18F-FLT, developed in the 1990s (18,19), a
number of markers have been used to predict the biologic
behavior of tumors and outcome following surgical
and medical treatments. At a basic histological level,
mitotic index and lymphovascular invasion are commonly
used to assess potentially aggressive tumors. Ki-67 is a
nuclear antigen only present in the nuclei of proliferating
cells, and good correlation between Ki-67 and S-phase
indices have been reported by flow cytometry (20). Ki-67
immunohistochemistry (IHC) has also been used to evaluate
a tumors’ proliferative activity.
Clinical evaluation and quantification of proliferative
activity and tumor invasiveness can be performed by using
FLT-positron emission tomography imaging. Similar to its
mother drug azidothymidine, 18F-FLT acts as a terminator
of the growing DNA chain. Actually, only a small amount
of 18F-FLT is accumulated in DNA; rather, it is retained
intracellularly after phosphorylation by thymidine kinase 1.
F-FLT pathway is similar to the imaging of glucose uptake
pathway with 18F-FDG after trapping by hexokinase.
Therefore, both compounds reflect accumulation by
transport and subsequent activation by the first step in
utilization pathways. 18F-FLT does not reflect the whole
DNA synthesis, just as 18F-FDG does not reflect the whole
glucose use. All clinical studies demonstrate a distinct BM
uptake on 18F-FLT images. Although the exact mechanism is
still being discussed, red marrow’s precursor cell population
with high proliferative activity is considered as the main
reason for 18F-FLT localization.
The primary aim of this study is to estimate the
distribution of hematopoietic cellular red BM and nonhematopoietic fibroareolar fatty yellow BM based on a
combination of 18F-FLT PET and 18F-FDG PET, which both
target BM compartment and evaluate the glycolytic and
proliferative properties of BM cells, respectively. In this pilot
study, a novel technique is proposed to estimate patient
specific BM volumes based on whole body 18F-FLT PET
and 18F-FDG PET. The whole bone compartment is first
separated into cortical bone and trabecular bone by using

Bone Marrow (BM) is of vital importance in oncological
applications since it is most sensitive to radiation and
chemotherapy, and often regarded as the dose-limiting
factor for systemic radionuclide therapies (1,2,3). Moreover,
estimating the volume of the highly active red BM is
essential in stem cell transplantation studies (4), as timely
stem cell support could improve patient recovery.
Furthermore, clinical studies, which aim to determine
the correlation between administered dose and sensitivity
to BM toxicity, can be confounded by potential effects of
previous treatments.
Despite the advances in the current BM evaluation
techniques, biopsy remains the gold standard for clinical
diagnosis of functional and morphologic status (5,6,7).
However, biopsy that is dependent on site-specific sampling
often fails to produce a correct estimation of the whole
body BM distribution due to non- homogeneity within the
skeletal system.
The International Commission on Radiological
Protection (ICRP) estimates that total red marrow, which is
the hematopoietically active tissue is 1.170 g in a healthy
40-year-old men and 900 g in women, and a total yellow
marrow of about 2.480 g in men, and 1.800 g in women
(8,9). Systemic radionuclide therapies mostly affect the red
BM, and thus, it is of critical importance to estimate its
volume in individuals undergoing treatment. As estimates
of BM vary between individuals, patient-specific estimation
of hematopoietically active red BM would enable better
characterization of the BM compartment and hence better
individualized dosimetry (10,11).
Magnetic
Resonance
Imaging
(MRI)
based
techniques that are capable of estimating water and
fat components of the bone may be able to estimate
BM volumes (12,13,14). However, the infrequent use
and long acquisition times of whole-body MRI hamper
their use for BM estimation applications. More recently,
quantitative SPECT based techniques using specific
radiopharmaceuticals have been developed, which target
the reticuloendothelial system as well as erythropoietic or
granulopoietic cells for BM estimation (10,15,16). These
techniques suffer from the limitation due to tracer kinetics
and the physics of single photon detection in SPECT.
Recently, a study by Sambuceti et al. estimated the BM
volume using 2-deoxy-2-(18F)-fluoro-D-glucose (18F-FDG)
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was obtained from Cardinal Health 414, LLC. 18F- FLT
administered activity was 10±1 mCi, and imaging time
point was 60±15 minutes post injection, whereas 18FFDG was administered with an activity of 10±1 mCi, and
imaging time point was 60±15 minutes post injection.
Images were obtained with 16-slice Siemens PET/CT. The
scanning parameters for CT imaging were 140 kVp, 80mA,
0.5s rotation time, and 512×512-pixel matrix.
B. Probabilistic LD A for Cortical and Trabecular
Bone Segmentation
Linear discriminant analysis (LDA) is a widely used
technique in pattern recognition, statistics and machine
learning to determine characteristic features that can
aid in difficult segmentation tasks (21,22,23,24,25). The
technique, as used in this study, exploits the fact that
Hounsfield values are different in cortical and trabecular
bone on CT images (26). This difference in Hounsfield value
can be used to train an LDA-based classifier for separating
the entire bone into cortical and trabecular compartments.
The proposed LDA classifier estimates a posterior
probability for each voxel of bone compartment on CT
images (Figure 2A), for segmentation of bone into either
cortical or trabecular compartments. In order to train the
classifier, 1000 voxels of CT skeleton in seven patients are
randomly chosen and manually assigned into one of the
two groups: Cortical (C) or Trabecular (T).
The training phase estimates the parameters of linear
discriminant functions for the two classes as given in
Equation 1.
dCL x,y,z=αC+ βC HVx,y,z, and
dTL x,y,z=αT+ βT HV(x,y,z) (1).
αC, βC, αT, βT are the LDA parameters for the two
groups cortical (C) and V(x,y,z) represents the Hounsfield
value of a particular voxel of the CT image. The pprior=0.5,
suggesting that a given voxel of the skeleton has an equal
probability of belonging to either one of the two classes.
The segmentation of the entire bone into cortical and
trabecular requires each pC or pT based on the linear score
LC and LT, respectively. The posterior probabilities signify
the likelihood of a voxel to belong to either of the groups.
The linear scores LC and LT are estimated based on the
Hounsfield value of the voxel under investigation as given
by Equation 2.
LC(x,y,z)= dCL x,y,z+log(pprior), and
LTx,y,z= dTL x,y,z+ log(pprior) (2).
The technique computes two 3D posterior probability
maps for every voxel of the skeleton. A higher posterior
probability determines the grouping of the voxel.
Following this probabilistic segmentation of the
skeleton into cortical and trabecular regions, a 3D
connected islanding algorithm is employed to remove any
spurious points marked erroneously as trabecular bone.
The algorithm removes all connected components of the
trabecular bone that have fewer than P voxels. The study
uses a 26-point neighborhood connectedness for complete

Computed Tomography (CT). The study assumes that
the BM resides within the trabecular compartment of
the bone and uses statistical thresholds on PET images to
estimate the total BM volume within the skeleton. Figure
1 depicts the general structure of BM estimation method.

Materials and Methods
A. Patient Population and Imaging Protocol
This investigation was performed on patients who
underwent 18F-FLT to determine the key imaging
characteristics of patients with pancreatic cancer. Eligibility
criteria included age ≥18, ability and willingness to give a
written consent, life expectancy >3 months, and Karnofsky
performance status ≥70. Patient demographics for the
studied population are presented in Table 1.
The patient population did not show presence of visible
bone metastases on either FDG or FLT PET/CT imaging. In
addition, Complete Blood Cell (CBC) counts of the subjects
reported an average glucose level of 117.85 mg/dL, a
mean RBC count of 4.54x109 cells/ml and a mean platelet
count of 385.85x109 per ml. The results of the CBC tests
along with absence of any bone metastases rendered
the population a viable choice for the study of on BM
compartment.
The study was performed under an FDA approved
Investigational New Drug (IND) and after IRB review and
approval. In this study, 3’-18F-fluoro-3’-deoxy-L- thymidine

Figure 1. General structure of the entire BM estimation approach, showing
the various steps of the algorithm for BM volume estimation
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extracts only the FLT/FDG activity located in the trabecular
bone by using the CT-based 3D posterior probability maps
obtained in the preceding step. Figure 2E shows the
resultant image obtained by masking the registered FLT-PET
images with the posterior probability map of the trabecular
tissue.
Thresholding in PET images has always been a topic
of great interest, with thresholds playing a critical role
in determining the correct volume/area of the extracted
object (27). Various studies with 18F-FLT have shown
different Standard Uptake Value (SUV) thresholds deemed
optimal for determining the functionally active BM (28,29).
In addition, studies have shown that the SUV threshold
varies for different bones of the body, therefore, no one
single SUV threshold could possibly be considered as the
gold standard (28).
To overcome the contentious issue of thresholds,
a completely statistically driven approach outlined by
Sambuceti et al. (17) has been adopted for both 18F-FLT
and 18F-FDG based BM estimation. The approach initially
estimates the mean (SUV) and standard deviation (SDvert)
of all the activity located within the trabecular bone, in the
thoracic and lumbar vertebrae regions as shown in Figure
2 (D). The technique estimates the red (active) BM volume
by accounting all voxels of the trabecular bone that are
above the threshold computed as SUVvert −2.5×SDvert.
A unique property for estimating the red BM in this study
is in the use of patient-specific thresholds rather than
a fixed threshold to account for differences in uptake
across patients. Less-active yellow BM is estimated as the
fraction of the trabecular bone volume below the red BM
threshold. Figure 2F illustrates the resultant image after the
thresholding operation showing the statistically significant
voxels of the BM.
D. Volume Estimation
Cost-effective third party software called ScanIP™
developed by Simpleware Ltd. based in the United Kingdom
is utilized for estimating the volume of the statistically
significant BM. The calculated volumes are in milliliters
(ml). Figure 2G shows 3D rendering of BM in the entire
body with red regions showing red BM and yellow regions

3D connectivity of every voxel that touches the faces,
edges, or corners of the voxel under consideration.
The estimation of the trabecular and cortical bone
regions is carried out for each patient by CTs co-registered
to both the 18F-FLT and 18F-FDG PETs. Figure 2B,C shows the
extracted cortical and trabecular regions of bone by using
the posterior probability masks generated with Equation 2.
C. Statistical BM Segmentation
Estimation of hematopoietically active BM is based
on the assumption that BM is located in the trabecular
compartment of bone, and 18F-FLT voxel intensities, as
seen on PET images, are correlated with the proliferative/
glycolytic activity of the BM. This estimation technique

Figure 2. Full body images at various steps of the BM extraction process
with the top row showing 18F-FLT and bottom row showing 18F-FDG results.
(A) CT image (B) Extracted cortical bone using probabilistic LDA (C) Extracted
trabecular bone following probabilistic LDA (D) Activity in trabecular bone
in thoracic and lumbar vertebrae regions (E) Activity in trabecular bone in
the rest of the body excluding thoracic and lumbar vertebrae regions (F)
Thresholded BM map generated after applying a statistical thresholding on
PET image. (G) 3D rendering of BM in the entire body, with red regions
showing red BM and yellow regions corresponding to yellow BM. The
cortical bone overlay is showing using a transparent white overlay

Table 1. Patient Demographics
Subject

Measured
Weight (kg)

Height (cm)

Gender

Age at time of
Imaging (years)

Ideal Body Weight
(kg)

Body Mass Index
(BMI) (kg/m2)

1

61.68

157

F

65

52.38

24.87

2

138.79

180

M

54

72.89

42.68

3

104.32

185

M

53

76.70

30.34

4

68.49

180

M

59

72.89

21.06

5

63.04

165

M

68

61.50

23.13

6

68.94

183

M

63

74.79

20.61

F

7

70.76

160

Average

82.29±28.79

172.85±11.76

59

54.11

27.66

60.14±5.55

146.54±2.62

27.19±7.66
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showing corresponding yellow BM. The cortical bone is
shown using a transparent white overlay.
E. Statistical Analysis
All results are presented in the form of mean ± standard
deviation. Linear regressions as performed in this study
make use of the least square technique and report the R2
of the fit and the p-value. All comparative results between
18F-FLT and 18F-FDG based estimations are carried out
through paired t-tests. A p-value of <0.05 is considered
statistically significant.
F. Ethics Statement
The research has been approved by the Western
Institutional Review Board. A Certificate of approval from
the WIRB has been obtained. Each participant provided
a written consent to participate in the study as per the
requirements and guidelines of the IRB.

respectively, showing the average red and yellow BM
volumes for each patient with the standard deviation
obtained upon executing the algorithm 50 times. The tables
also provide the volumes of the trabecular bone region
along with the fraction of red BM within the trabecular
region.
In addition, it is seen that the estimates of Trabecular
Bone Volume (IBV) from the CT images co-registered to
either FLT or FDG PET/CT were not significantly different
(p=0.49). Additionally, it is seen that 18F-FLT based
measures of red BM volume (RBV) were higher than those
obtained by 18F-FDG (∆=89.21 ml), but results of a paired
t-test demonstrate that they were not significantly different
(p=0.55). Consecutively, estimated total body yellow BM
volume (YBV) from the two different tracers namely 18F-FLT
and 18F-FDG were not significantly different (p=0.112).
The red BM fraction estimated from 18F-FLT was higher

Results
G. Probabilistic LD A Segmentation
To assess the results of the Probabilistic LDA used for
segmenting the bone into cortical and trabecular regions,
the leave-one-out cross-validation (LOOCV), which is a
trusted model for assessing the performance of classifiers,
is used in this study. The classification experiment was
implemented 50 times on 50 random training sets of
1000 samples. Table 2 provides the average training and
LOOCV testing metrics (accuracy, sensitivity, specificity and
precision) of the classification results performed across all
the 14 CT scans (seven co-registered to 18F-FLT and seven
co-registered to 18F-FDG).
H. Whole Body BM Volumetric Assessment
Estimated BM volumes for the study patients are
illustrated in Tables 3 and 4 using 18F-FLT and 18F-FDG,
Table 2. Classification performance
Accuracy

Sensitivity

Specificity

Precision

Training

0.94±0.04

0.96±0.02

0.91±0.04

0.92±0.05

LOOCV

0.92±0.04

0.93±0.03

0.90±0.07

0.91±0.04

Figure 3. Influence of (A) Measured Body Weight, and (B) Body Mass
Index (BMI) on Red BM Volume (RBV) obtained from 18F-FLT imaging in all
subjects, whereas (C) and (D) show the influence of measured body weight
and BMI in only males, respectively. The RBVs showed better correlation to
physical measurements when female subjects were excluded

Table 3. Estimated Whole Body BM volumes using 18F-FLT PET/CT imaging
Marrow Volumes
Patient

Gender

Red (RBV)

Yellow (YBV)

Trabecular Bone Volume (IBV)

Red BM Fraction
88 (RBV/IBV)

1

F

1136.37±17.7

513.63±22.87

1650±22.67

0.69

2

M

421.16±26.94

598.84±16.11

1020±23.27

0.41

3

M

799.73±12.61

820.27±18.8

1620±16.21

0.49

4

M

697.94±33.64

682.06±22.7

1380±28.44

0.51

5

M

778.07±28.53

551.93±18.83

1330±24.76

0.59

6

M

849.31±21.7

640.69±11.64

1490±19.54

0.57

7

F

486.52±29.63

143.48±23.35

630±25.67

0.77

738.44±220.95

564.42±195.19

1302.86±337.12

0.58±0.11

Average
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than that estimated from 18F-FDG but was not statistically
different for the 7 patients in the study. (∆=0.08; p=0.25).
I. Effects of Weight, Height, and BMI on Whole
Body BM Volumes
For 18F-FLT based BM measurements it is seen that
although the RBV was not affected by gender (p=0.653),
the YBV was significantly different between males and
the females (p<0.05). Also, the RBV did not show a good
correlation with the measured weight (R2=0.32; Figure 3A),

measured height (R2=0.06), Body Mass Index (R2=0.34;
Figure 3B) and ideal body weight (R2=0.05). Similar trends
were seen for YBV and IBV for the subjects in this study.
However, on the exclusion of female subjects (n=2) from
regression analysis, it is observed that a higher correlation
was obtained for RBV with measured weight (R2=0.61;
Figure 3C) and the BMI (R2=0.70; Figure 3D).
Finally, the red BM fraction was found to be loosely
correlated with the measured weight (R2=0.49; Figure 4A)
and well correlated to the measured height (R2=0.68) and
the ideal body weight (R2=0.73; Figure 4B). It was also
significantly different between males and females, with
females showing much higher red bone matter within
trabecular bone (p<0.05).
For 18F-FDG based BM measurements, it was seen that
RBV was significantly different between males and females
(p<0.05), however YBV and IBV were not statistically
different between the two genders. Also for 18F-FDG, RBV
did not correlate well with measured weight (R2=0.24),
and Body Mass Index (R2=0.08) and correlated weakly
with measured height (R2=0.43) and ideal body weight
(R2=0.47).
An interesting feature is seen among males in the
study population, where stronger correlation of the IBV
with measured weight (R2=0.77), and BMI (R2=0.61) were
observed. Also, red BM fraction was not strongly correlated
to any demographic features when measured using 18F-FDG
PET/CT (Figure 4C and 4D).
J. SUV Assessment
The SUV measure of 18F-FLT images is an indicator of
the proliferative activity of BM, whereas the SUV measure
in 18F-FDG imaging is indicative of the glycolytic activity
of the BM compartment. Table 5 shows the mean SUV
values corresponding to the spinal column and the rest
of the body (ROB). Results show that the spinal activity
SUV that is used to determine the threshold for red BM
segmentation was significantly different between 18F-FLT
PET and 18F-FDG PET (p<0.05). Also, the SUV for the rest
of the body (excluding the skull) was found to be different
between the two imaging tracers. Moreover, the results
of an ANOVA for both FDG and FLT based BM estimation
suggest that the mean spinal and rest-of-body SUVs were
not different among males and females.
In addition, as seen in Figure 5, red BM volumes were
not very well correlated to the mean spinal SUVs for 18F-FLT
(R2=0.13; Figure 5A), but were comparatively better
correlated in the case of 18F-FDG (R2=0.71; Figure 5C).
Also, the yellow BM volumes were not very well correlated
with the mean SUVs of the rest of the body for both FLTand FDG-based estimations (Figure 5B and 5D).
An important finding is that the SUV values in the
spine and rest of the body vary significantly for different
subjects. This variation is an important aspect that needs to
be considered when 18F-FLT images are thresholded using
fixed SUV values. This variation in the different statistically

Figure 4. Correlation between Red BM Fraction and (A) Measured Weight
and (B) Ideal Body Weight using 18F-FLT PET imaging. Parts (C) and (D) show
the same correlation on 18F-FDG PET. A higher correlation was detected
between RBV and measured weight and ideal body weight in 18F-FLT based
RBV estimations as compared to 18F-FDG imaging

Figure 5. Correlation between (A) Red BM Volume (RBV) to mean spinal
SUV and (B) Yellow BM Volume (YBV) to mean rest of body SUV for 18F-FLT
imaging. Parts (C) and (D) show the same result for 18F-FDG imaging. RBV
are well-correlated for 18F-FDG but not for 18F-FLT imaging
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meaningful SUV thresholds combined with the fact that the
mean SUV value in the trabecular bone varies significantly
from patient to patient, suggests that the use of statistical
thresholds, like the one suggested in this article, may be
advantageous for obtaining more meaningful results.

lower Hounsfield value (11,26). This assumption along with
the probabilistic training approach enables the technique to
be applied on every single slice of the CT image without
any human intervention, once the classifier is trained.
Also, as seen in the results, the IBV estimations are
not significantly different between those estimated from
CTs co-registered to 18F-FLT and 18F-FDG PETs. This finding
is expected in such studies since the discrepancies in
measurements of the IBV can result in incorrect estimations
of BM volumes. Also, since the imaging of FLT and FDG
PET/CT is not performed more than a week apart, no
expected discrepancies should be observed in the CT-based
bone volume measurements as seen in the results. The
insignificant differences may be due to the probabilistic
nature of the segmentation algorithm for delineating
cortical from trabecular bone.
Moreover, the probabilistic LDA based technique classifies
the brain as trabecular bone as can be seen in Figure 2C,
but it is not a major source of error in BM estimation due to
the targeted uptake of 18F-FLT. Brain tissue does not show
significant uptake of 18F- FLT, as in the case of FDG, which
is the primary reason why the skull needs to be omitted
from the quantification purposes. The use of 18F-FLT offers
a unique opportunity to quantify the BM volume (albeit
negligible) in the skull, which is not estimated in studies
based on FDG. It is seen in this study that indeed negligible
BM is found in the skull, which is conform to the proposed
BM distribution, as was also confirmed in other studies

Discussion
To the best of our knowledge of the literature, this study
is the first to compare total body BM volume estimations
obtained from the use of 18F-FLT PET/CT and 18F-FDG
PET/CT. The study presented an augmented approach for
eliciting a better understanding of the BM compartment
by combining the glycolytic activity of 18F-FDG PET and
proliferative activity of 18F-FLT PET, each being acquired
within a week’s duration for the same patient. Other
studies using 18F-FLT for imaging the BM compartment
have focused on particular regions of interest rather than
providing a measure of the total active BM in the human
body (28,30). Also, the nature of the proposed technique
renders it possible to extract and quantify the active BM
within any bone in the body.
An important contribution relates to the use of the
probabilistic LDA technique for extracting compact and
trabecular bone compartments. This probabilistic technique
is based on the assumption that compact bone in CT
images appears as having the highest Hounsfield value and
that trabecular bone located in its cavity has a significantly

Table 4. Estimated Whole Body BM volumes using 18F-FDG PET/CT imaging
Marrow Volumes
Patient

Gender

Red (RBV)

Yellow (YBV)

Trabecular Bone Volume (IBV)

Red BM Fraction (RBV/IBV)

1

F

405.2±21.49

1155±24.93

1560.2±19.01

0.25

2

M

922.2±15.63

728.3±18.22

1650.5±21.63

0.55

3

M

625.6±17.97

965±18.38

1590.6±19.72

0.39

4

M

537.9±22.69

833.1±26.1

1371±16.45

0.39

5

M

723.4±19.76

597±21.94

1320.5±18.24

0.54

6

M

937±22.81

573.1±21.53

1510.1±21.72

0.62

7

F

393.4±17.93

214.6±18.94

608±18.59

0.64

649.23±207.30

723.75±281.35

1372.98±330.85

0.49±0.13

Average

Table 5. SUV measures
PET Tracer
18F-FDG

18F-FLT

p-value (FDG vs. FLT)

Overall

Male

Female

p-value (Male vs. Female)

Spinal

1.74±0.26

1.83±0.25

1.51±0.04

0.152

ROB

0.69±0.29

0.75±0.33

0.54±0.06

0.438

Spinal

2.92±0.44

3.05±0.44

2.56±0.29

0.245

ROB

1.00±0.13

0.96±0.14

1.09±0.02

0.265

Spinal

< 0.05

ROB

< 0.05
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(17,28). The quantitative measurement of the total active
BM volume in the body has not been clearly defined in the
literature. The primary description of the BM compartment
and its related measures come from the 1926 study by
Mechanik and its various reviews by Woodward and
Holodny, Cristy and Ellis (31,32,33,34).
Mechanik’s study that is based on 13 subjects who died
of non-hematological diseases is the fundamental study on
which all BM estimates are based (33). A recent study by
Sambuceti et al. estimated the BM volume using FDG PET/
CT. This study that was based on a large population was
first of its kind to estimate intraosseous volume (IBV) using
SUV measures obtained from glucose uptake (17).
This study showed that 18F-FLT based BM estimations
were higher than those obtained from 18F-FDG PET
imaging, all but for two patients. The differences between
the BM estimations for the two imaging modalities may be
a result of the difference in the distribution and mechanism
of the PET tracer within the body.
18F-FLT enables us to visualize the true hematopoietically
active BM compartment of the body in order to estimate
the whole body volume. Additionally, the assessment of the
RBV was very close to the one obtained by Sambuceti et
al., which showed that the mean RBV was approximately
541±195 ml.
The measured BM volumes in this study are slightly
lower than those reported from other studies, which are
based on cadaver studies. There are various reasons that
could account for such differences. The difference in values
from the Mechanik data can be explained due to the
different methods used. Mechanik employed prolonged
boiling of the bone in a post-mortem analysis whereas the
presented technique involves metabolic imaging.
This study also showed that the RBV volumes estimated
by FLT were not significantly different between males and
females as was the case using FDG. Other studies based on
FDG have showed that assessments of BM were significantly
different between the two genders as was confirmed here
in this study (17). Also, we found that the mean SUVs of
the spinal region and the rest of the body were significantly
different between FLT- and FDG-based imaging. The higher
mean SUV when using FLT signifies that FLT is a better
targeting agent for BM estimation as compared to FDG. Also,
the ratio of the mean spinal activity SUV to the mean SUV
of the rest of body is higher in FLT imaging (2.92 vs. 2.52 for
FDG), which may provide a higher contrast in estimating red
BM and hence an improved estimation of RBV.
Although the proposed approach of this study is based
on finding statistically meaningful BM volumes, it does
have some intrinsic limitations. The primary limiting factor
is the effect of partial volume averaging, which is observed
both in CT and PET images (35). This may often lead to
an overestimation of the cortical and trabecular regions
and in turn the BM volumes. Also, motion artifacts due
to the long imaging time of the PET as compared to CT
is another potential source of estimation error (36). The

probabilistic LDA technique has a cross-validated accuracy
of 91%, which may be attributed to errors in estimating
the boundary between the cortical and trabecular bone
regions, which in turn could lead to errors in BM volume
measurements. Finally, the size of the population of this
pilot study is a primary limitation and current findings
are needed to be verified through the inclusion of more
subjects as they become available, and as we continue to
augment our understanding of pancreatic cancer in order
to offer better and more effective means for diagnosis and
ultimately better treatment. The small number of patients
included in this pilot study is dictated primarily by the
nature of the disease which observes the lack of simple
early detection methods and the earliest indications of
disease being nonspecific. Also, the intensive nature of the
imaging task with both 18F-FLT and 18F-FDG PET/CT may
have been a limiting factor for inclusion of subjects.
Although some limitations exist, the study provides a
unique quantitative assessment of the whole-bone marrow
compartment using its proliferative and glycolytic activity in
the same patients to provide new insights in the distribution
of the active bone marrow for various applications.
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